SEC Form 4 · accession 0000899243-15-007464
Clovis Oncology, Inc. · CLVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Erle T Mast
Officer — Executive VP and CFO
Period of report
Nov 2, 2015
Accepted (ET)
Nov 3, 2015 · 4:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001466301
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF6 | Nov 2, 2015 | S | 89 | $98.82 | D | 138,494 | D | |
| Common StockF1,F6 | Nov 2, 2015 | S | 111 | $100.8027 | D | 138,383 | D | |
| Common StockF6 | Nov 2, 2015 | S | 100 | $102.67 | D | 138,283 | D | |
| Common StockF2,F6 | Nov 2, 2015 | S | 500 | $104.284 | D | 137,783 | D | |
| Common StockF3,F6 | Nov 2, 2015 | S | 400 | $105.095 | D | 137,383 | D | |
| Common StockF4,F6 | Nov 2, 2015 | S | 1,000 | $106.3302 | D | 136,383 | D | |
| Common StockF5,F6 | Nov 2, 2015 | S | 700 | $107.2886 | D | 135,683 | D | |
| Common StockF6 | Nov 2, 2015 | S | 100 | $108.16 | D | 135,583 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $100.00 to $100.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2This transaction was executed in multiple trades at prices ranging from $103.75 to $104.44. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $104.83 to $105.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $105.86 to $106.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $106.96 to $107.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2014.